Zobrazeno 1 - 10
of 94
pro vyhledávání: '"Mikhail N, Kosiborod"'
Autor:
Ali Javaheri, Mualla Ozcan, Lauren Moubarak, Karen E. Smoyer, Michelle I. Rossulek, James H. Revkin, John D. Groarke, Lisa C. Tarasenko, Mikhail N. Kosiborod
Publikováno v:
Heliyon, Vol 10, Iss 16, Pp e35916- (2024)
Growth differentiation factor-15 (GDF-15) is an emerging biomarker in several conditions. This SLR, conducted following PRISMA guidelines, examined the association between GDF-15 concentration and range of adverse outcomes in patients with heart fail
Externí odkaz:
https://doaj.org/article/a13cd2767fc04939926e228b16fc96b5
Autor:
Ankeet S. Bhatt, Muthiah Vaduganathan, Brian L. Claggett, Ian J. Kulac, Inder S. Anand, Akshay S. Desai, James C. Fang, Adrian F. Hernandez, Pardeep S. Jhund, Mikhail N. Kosiborod, Marc S. Sabatine, Sanjiv J. Shah, Orly Vardeny, John J. V. McMurray, Scott D. Solomon, Thomas A. Gaziano
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 5 (2024)
Background The sodium glucose cotransporter‐2 inhibitors are guideline‐recommended to treat heart failure across the spectrum of left ventricular ejection fraction; however, economic evaluations of adding sodium glucose cotransporter‐2 inhibito
Externí odkaz:
https://doaj.org/article/53dbb9210acf48109e85b415aa980e57
Autor:
Marcus Lind, Mark A Clements, Diana Ferro, Osagie Ebekozien, Erin M Tallon, Mary Pat Gallagher, Vincent S Staggs, Deepa Badrinath Murthy, Mikhail N Kosiborod, Camila Manrique-Acevedo, Chi-Ren Shyu
Publikováno v:
BMJ Open, Vol 13, Iss 7 (2023)
Objectives We sought to examine in individuals with SARS-CoV-2 infection whether risk for thrombotic and thromboembolic events (TTE) is modified by presence of a diabetes diagnosis. Furthermore, we analysed whether differential risk for TTEs exists i
Externí odkaz:
https://doaj.org/article/1137a6602f894c078f4fa8334cd94b48
Autor:
Subodh Verma, Meena Bhatta, Melanie Davies, John E. Deanfield, W. Timothy Garvey, Camilla Jensen, Kristian Kandler, Robert F. Kushner, Domenica M. Rubino, Mikhail N. Kosiborod
Publikováno v:
EClinicalMedicine, Vol 55, Iss , Pp 101737- (2023)
Summary: Background: Inflammation is a key driver of atherosclerotic cardiovascular disease. C-reactive protein (CRP), an established biomarker of inflammation, is commonly elevated in people with overweight/obesity. Methods: STEP 1, 2, and 3 were 68
Externí odkaz:
https://doaj.org/article/60feb89664bd496d9129a6ab9fd90750
Autor:
Subodh Verma, Lawrence A. Leiter, Bernard Zinman, Abhinav Sharma, Michaela Mattheus, David Fitchett, Jyothis George, Anne Pernille Ofstad, Mikhail N. Kosiborod, Christoph Wanner, Silvio E. Inzucchi
Publikováno v:
ESC Heart Failure, Vol 8, Iss 4, Pp 2603-2607 (2021)
Abstract Aims In the EMPA‐REG OUTCOME trial, in patients with type 2 diabetes and established atherosclerotic cardiovascular (CV) disease, empagliflozin vs. placebo reduced the risk of hospitalization for heart failure (HHF) by 35%, CV death/HHF by
Externí odkaz:
https://doaj.org/article/35bbcdb9f370489588adedc3953e2157
Autor:
Andrew Kosmopoulos, Deepak L. Bhatt, Gus Meglis, Raj Verma, Yi Pan, Adrian Quan, Hwee Teoh, Maya Verma, Lixia Jiao, Robert Wang, Rebecca A. Juliano, Mahesh Kajil, Mikhail N. Kosiborod, Basel Bari, Abdullahi A. Berih, Mallory Aguilar, Antonnette Escano, Andrew Leung, Idelta Coelho, Makoto Hibino, Rafael Díaz, R. Preston Mason, Ph. Gabriel Steg, Tabassome Simon, Alan S. Go, Andrew P. Ambrosy, Richard Choi, Arthur M. Kushner, Lawrence A. Leiter, Mohammed Al-Omran, Subodh Verma, C. David Mazer
Publikováno v:
iScience, Vol 24, Iss 9, Pp 103040- (2021)
Summary: The coronavirus disease 2019 (COVID-19) pandemic remains a source of considerable morbidity and mortality throughout the world. Therapeutic options to reduce symptoms, inflammatory response, or disease progression are limited. This randomize
Externí odkaz:
https://doaj.org/article/26ff798370704467a00107bd76266791
Autor:
Jawad H. Butt, Kieran F. Docherty, Brian L. Claggett, Akshay S. Desai, Magnus Petersson, Anna Maria Langkilde, Rudolf A. de Boer, Adrian F. Hernandez, Silvio E. Inzucchi, Mikhail N. Kosiborod, Lars Køber, Carolyn S. P. Lam, Felipe A. Martinez, Piotr Ponikowski, Marc S. Sabatine, Sanjiv J. Shah, Muthiah Vaduganathan, Pardeep S. Jhund, Scott D. Solomon, John J. V. McMurray
Publikováno v:
JAMA Cardiology, 8(4), 386-393. American Medical Association
ImportanceGout is common in patients with heart failure (HF), and sodium-glucose cotransporter 2 inhibitors, a foundational treatment for HF, reduce uric acid levels.ObjectiveTo examine the reported prevalence of gout at baseline, the association bet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f816e47694d957b2ef24a33e471ed5c
http://www.scopus.com/inward/record.url?scp=85152489603&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85152489603&partnerID=8YFLogxK
Autor:
Toru Kondo, Karola S. Jering, C. Jan Willem Borleffs, Rudolf A. de Boer, Brian L. Claggett, Akshay S. Desai, Dan Dobreanu, Silvio E. Inzucchi, Adrian F. Hernandez, Stefan P. Janssens, Pardeep S. Jhund, Mikhail N. Kosiborod, Carolyn S.P. Lam, Anna Maria Langkilde, Felipe A. Martinez, Magnus Petersson, Pham Nguyen Vinh, Muthiah Vaduganathan, Scott D. Solomon, John J.V. McMurray
Publikováno v:
Circulation, 147(14), 1067-1078. Lippincott Williams & Wilkins
Background: How patient characteristics and outcomes vary according to the duration of heart failure (HF) is unknown in individuals with mildly reduced or preserved ejection fraction. We compared these, and the efficacy and safety of dapagliflozin, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c56ea2b829a00b65eb433b8d3070b59a
http://www.scopus.com/inward/record.url?scp=85151327309&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85151327309&partnerID=8YFLogxK
Autor:
Jawad H. Butt, Kieran F. Docherty, Brian L. Claggett, Akshay S. Desai, James C. Fang, Magnus Petersson, Anna Maria Langkilde, Rudolf A. de Boer, Jose Walter Cabrera Honorio, Adrian F. Hernandez, Silvio E. Inzucchi, Mikhail N. Kosiborod, Lars Køber, Carolyn S.P. Lam, Felipe A. Martinez, Piotr Ponikowski, Marc S. Sabatine, Orly Vardeny, Eileen O'Meara, Jose F.K. Saraiva, Sanjiv J. Shah, Muthiah Vaduganathan, Pardeep S. Jhund, Scott D. Solomon, John J.V. McMurray
Publikováno v:
JACC: Heart Failure. 11:375-388
Background: Black people have a higher incidence and prevalence of heart failure (HF) than White people, and once HF has developed, they may have worse outcomes. There is also evidence that the response to several pharmacologic therapies may differ b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c83593bbced871479864f3145e8a3ea4
https://doi.org/10.1016/j.jchf.2022.11.014
https://doi.org/10.1016/j.jchf.2022.11.014
Autor:
Senthil, Selvaraj, Zhuxuan, Fu, Philip, Jones, Lydia C, Kwee, Sheryl L, Windsor, Olga, Ilkayeva, Christopher B, Newgard, Kenneth B, Margulies, Mansoor, Husain, Silvio E, Inzucchi, Darren K, McGuire, Bertram, Pitt, Benjamin M, Scirica, David E, Lanfear, Michael E, Nassif, Ali, Javaheri, Robert J, Mentz, Mikhail N, Kosiborod, Svati H, Shah
Publikováno v:
Circulation. 146(11)
Background: Sodium-glucose cotransporter-2 inhibitors are foundational therapy in patients with heart failure with reduced ejection fraction (HFrEF), but underlying mechanisms of benefit are not well defined. We sought to investigate the relationship
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21f8b9870ff2acbe19e09e991ae63ed8
https://pubmed.ncbi.nlm.nih.gov/36095068
https://pubmed.ncbi.nlm.nih.gov/36095068